100+ Free ABPS Radiation Oncology Practice Questions

Pass your ABPS Radiation Oncology Certification Examination exam on the first try — instant access, no signup required.

✓ No registration✓ No credit card✓ No hidden fees✓ Start practicing immediately

Historically high first-time pass rate for residency-trained radiation oncologists (BCRO does not publish exact statistics) Pass Rate

100+ Questions

100% Free

1 / 100

Question 1

Score: 0/0

Which type of DNA damage is the principal lethal lesion produced by ionizing radiation?

Single-strand breaks

Double-strand breaks

Base modifications

Cross-links only

to track

Same family resources

More ABPS Board Certifications Prep

Continue through related practice pages, study guides, comparisons, and articles from the same exam family.

Practice Pages

ABPS Administrative Medicine Practice100 questions ABPS Anesthesiology (BCA) Practice100 questions ABPS Dermatology (BCD) Practice100 questions ABPS Diagnostic Radiology (BCDR) Practice100 questions ABPS Disaster Medicine Practice100 questions ABPS Emergency Medicine (BCEM) Practice100 questions

2026 Statistics

Key Facts: ABPS Radiation Oncology Exam

1.1

Clinical Proton RBE

Conventional proton therapy clinical RBE vs photons

~10 Gy

Alpha/Beta Most Tumors

Linear-quadratic model — early-responding tissues and most tumors

8 Gy x 1

Bone Met Single Fraction

Dutch BMS, RTOG 9714, ASTRO Choosing Wisely

26 Gy / 5

FAST-Forward Breast Regimen

Lancet 2020 — non-inferior to 40 Gy/15 fx

50 mSv

Annual Occupational Limit

NRC 10 CFR 20.1201 whole-body TEDE

~$2,500

2026 Exam Fee

ABPS/BCRO (verify current schedule)

The ABPS Radiation Oncology Certification Exam is a computer-based test administered by BCRO/ABPS for residency-trained radiation oncologists. Content blueprints across radiobiology and physics, treatment planning (3DCRT/IMRT/VMAT/SBRT/brachytherapy/protons), CNS tumors, head and neck, breast, thoracic, GI, GU, gynecologic, hematologic, pediatric tumors, palliative radiation, normal tissue tolerance, and radiation safety/QA. The 2026 fee is approximately $2,500; eligibility requires accredited radiation oncology residency training and an unrestricted medical license.

Sample ABPS Radiation Oncology Practice Questions

Try these sample questions to test your ABPS Radiation Oncology exam readiness. Each question includes a detailed explanation. Start the interactive quiz above for the full 100+ question experience with AI tutoring.

1Which type of DNA damage is the principal lethal lesion produced by ionizing radiation?

A.Single-strand breaks

B.Double-strand breaks

C.Base modifications

D.Cross-links only

Explanation: Double-strand DNA breaks (DSBs) are the principal lethal lesion of ionizing radiation. Although single-strand breaks and base damages occur much more frequently, they are usually faithfully repaired. Unrepaired or misrepaired DSBs lead to chromosomal aberrations, mitotic catastrophe, apoptosis, and clonogenic cell death.

2The 4 R's of classical radiobiology are best described as:

A.Repair, Redistribution, Repopulation, Reoxygenation

B.Repair, Replication, Recombination, Resistance

C.Recovery, Reoxygenation, Resistance, Redistribution

D.Repair, Redistribution, Repopulation, Radiosensitivity

Explanation: Withers' classical 4 R's are Repair (of sublethal damage between fractions), Redistribution (of cells through the cell cycle), Repopulation (proliferation of surviving clonogens), and Reoxygenation (of hypoxic tumor cells). Steel later added intrinsic Radiosensitivity as a 5th R.

3In the linear-quadratic model, the alpha/beta ratio for most early-responding tissues and most tumors is approximately:

A.1-3 Gy

B.3-5 Gy

C.10 Gy

D.20 Gy

Explanation: Early-responding tissues (skin, mucosa, bone marrow) and most tumors have a high alpha/beta ratio of approximately 10 Gy, making them relatively insensitive to fraction size. Late-responding tissues (spinal cord, kidney, lung fibrosis) have a low alpha/beta of 2-3 Gy, making them very sensitive to fraction size.

4What is the approximate oxygen enhancement ratio (OER) for X-rays at clinically relevant doses?

A.1.0

B.1.5

C.2.5-3.0

D.5.0

Explanation: The OER for low-LET radiation (X-rays, gamma rays) at clinical doses is approximately 2.5-3.0, meaning hypoxic cells require about 2.5-3 times the dose to achieve the same kill as oxygenated cells. The OER decreases with high-LET radiation (e.g., approximately 1.0 for alpha particles).

5Which phase of the cell cycle is generally MOST radiosensitive?

A.Early S

B.Late S

C.G1

D.G2/M

Explanation: Cells in G2 and mitosis (M) are most radiosensitive, while cells in late S phase are most radioresistant due to active homologous recombination repair. Redistribution through the cell cycle between fractions is one of the 4 R's that contributes to fractionation efficacy.

6The relative biological effectiveness (RBE) of protons compared to photons is conventionally taken as:

A.1.0

B.1.1

C.2.0

D.3.0

Explanation: Clinically, proton therapy uses a generic RBE of 1.1, meaning protons are approximately 10% more biologically effective than photons of the same physical dose. RBE actually varies along the proton track and may be higher near the distal Bragg peak edge, an active research topic.

7The depth of maximum dose (Dmax) for a 6 MV photon beam is approximately:

A.0.5 cm

B.1.5 cm

C.3.0 cm

D.5.0 cm

Explanation: Dmax for a 6 MV photon beam is approximately 1.5 cm. For 10 MV it is roughly 2.5 cm, and for 18 MV around 3.0-3.5 cm. The skin-sparing effect of megavoltage beams arises because dose builds up over this depth as charged particle equilibrium is established.

8What is the defining physical property of a proton beam that gives it a Bragg peak?

A.Constant LET throughout the beam path

B.Energy deposition that increases sharply near the end of range with rapid dose fall-off

C.Exponential attenuation similar to photons

D.Continuous build-up region with no skin sparing

Explanation: Protons deposit most of their energy at the end of their range (the Bragg peak), with relatively low entrance dose and essentially no exit dose. Spread-out Bragg peaks (SOBP) are produced by combining beams of different energies to cover the target while sparing distal tissues.

9ICRU 50/62/83 defines which volume as the GTV plus a margin for subclinical microscopic disease?

A.GTV (Gross Tumor Volume)

B.CTV (Clinical Target Volume)

C.PTV (Planning Target Volume)

D.ITV (Internal Target Volume)

Explanation: Per ICRU 50/62/83, CTV = GTV + margin for subclinical microscopic spread. The PTV adds a setup/uncertainty margin around the CTV (or ITV when motion is incorporated). GTV is gross visible disease; ITV accounts for internal organ motion.

10Which technique uses inverse planning with multiple beam angles and modulated fluence delivered while the gantry rotates?

A.3D conformal radiotherapy (3DCRT)

B.Static-field IMRT

C.Volumetric Modulated Arc Therapy (VMAT)

D.Conventional 2D RT

Explanation: VMAT delivers IMRT during continuous gantry rotation, with simultaneous modulation of MLC leaves, gantry speed, and dose rate. It typically provides faster treatment delivery and similar or better conformity compared to fixed-field IMRT.

About the ABPS Radiation Oncology Exam

The ABPS Radiation Oncology Certification Examination, administered by the Board of Certification in Radiation Oncology (BCRO) under the American Board of Physician Specialties (ABPS), validates competencies for radiation oncologists practicing across the discipline. Content spans radiobiology and radiation physics (DNA damage, the 4 R's of fractionation, linear-quadratic model, oxygen enhancement ratio, RBE/LET, Bragg peak, AAPM TG-51 dosimetry), treatment planning (3DCRT, IMRT, VMAT, SBRT/SABR, brachytherapy LDR/HDR, proton therapy, MR-Linac adaptive RT, ICRU 50/62/83 target volumes, IGRT/CBCT, DIBH), site-specific oncology (CNS tumors per Stupp/RTOG 9802/NRG CC001, head and neck per RTOG 1016/De-ESCALaTE, breast per START B/Canadian/FAST-Forward/Darby, thoracic per PACIFIC/Turrisi/SABR-COMET, GI per CROSS/PRODIGE 23/RAPIDO/Nigro, GU per CHHiP/PACE-B/EORTC 22863/STAMPEDE/FLAME, gynecologic per EMBRACE/PORTEC, pediatric per COG/AEWS, hematologic per HD10/ISRT/TBI/TSEBT, palliative per Dutch BMS/SCORAD), normal tissue tolerance and toxicity (QUANTEC constraints, pneumonitis, dermatitis, xerostomia, cardiac dose, re-irradiation), and radiation safety/QA (10 CFR Parts 20/35, AAPM TG-43/51/100/142, RO-ILS, ALARA, medical event reporting, Authorized User status). Eligibility requires an MD/DO with unrestricted license and completion of an accredited radiation oncology residency or equivalent BCRO-recognized training pathway.

Questions

200 scored questions

Time Limit

~4 hours CBT

Passing Score

Criterion-referenced scaled score set by BCRO (modified Angoff standard)

Exam Fee

~$2,500 examination fee (ABPS/BCRO 2026 — verify current schedule) (American Board of Physician Specialties (ABPS) — Board of Certification in Radiation Oncology (BCRO))

ABPS Radiation Oncology Exam Content Outline

~12%

Radiobiology & Radiation Physics

Double-strand DNA breaks as principal lethal lesion, Withers' 4 R's (Repair, Redistribution, Repopulation, Reoxygenation) plus intrinsic Radiosensitivity, linear-quadratic model and alpha/beta ratios (~10 Gy early/tumor, 2-3 Gy late), oxygen enhancement ratio (~2.5-3 for X-rays), cell-cycle radiosensitivity (G2/M most sensitive, late S resistant), LET and RBE (proton clinical RBE 1.1), Bragg peak and SOBP, photon Dmax (1.5 cm at 6 MV), HVL and beam quality, electron beam range, BED and EQD2 calculations.

~12%

Treatment Planning & Delivery

ICRU 50/62/83 GTV/CTV/ITV/PTV definitions, 3DCRT vs IMRT vs VMAT, SBRT/SABR for lung/liver/spine, brachytherapy LDR/MDR/HDR (Ir-192, I-125, Pd-103), TG-43 brachytherapy dosimetry, proton therapy (PBS/passive scatter, RBE 1.1, distal Bragg peak uncertainty), MR-Linac adaptive replanning (Elekta Unity, ViewRay MRIdian), CBCT-based IGRT and PTV-margin reduction, deep inspiration breath-hold, motion management (4DCT, gating, ITV), dose calculation algorithms (AAA, Acuros, Monte Carlo), inverse planning.

~8%

CNS Tumors

Glioblastoma Stupp protocol (60 Gy/30 fx + concurrent and adjuvant temozolomide; MGMT methylation), low-grade glioma RTOG 9802 (RT + PCV; IDH-mutant 1p/19q-codeleted), brain metastases — RTOG 9508 (WBRT+SRS), RTOG 9005 SRS doses (24/18/15 Gy by size), NRG CC001 hippocampal-avoidance WBRT + memantine, RTOG 0614 memantine, pituitary adenoma FSRT/SRS with optic constraints, ependymoma focal RT, meningioma fractionated/SRS, vestibular schwannoma SRS.

~8%

Head & Neck Cancer

Locally advanced HNSCC concurrent cisplatin 100 mg/m^2 q3 weeks + 70 Gy/35 fx, RTOG 1016 / De-ESCALaTE — cisplatin superior to cetuximab in HPV+ oropharynx, T1 glottic larynx hypofractionated lateral fields (e.g., 63 Gy at 2.25 Gy/fx, Yamazaki), nasopharyngeal carcinoma — concurrent cisplatin + IMRT 70 Gy with induction gem/cis (Zhang 2019), EBV DNA biomarker (NRG-HN001), parotid sparing (QUANTEC mean <26 Gy), elective nodal coverage.

~8%

Breast Cancer

Hypofractionated whole-breast 40-42.5 Gy/15-16 fx (START B, Canadian), ultra-hypofractionated 26 Gy/5 fx (FAST-Forward), DIBH for left-sided breast (Darby — 7.4% per Gy increase in major coronary events), regional nodal irradiation (EORTC 22922 Poortmans, MA.20), partial breast irradiation (ASTRO 2017/2023 — APBI for low-risk), DCIS post-BCS RT (NSABP B-17), EBCTCG meta-analysis (4:1 benefit), boost to lumpectomy cavity, postmastectomy RT for high-risk, ALND vs SLNB (Z0011).

~8%

Thoracic Malignancies

Early-stage NSCLC SBRT (RTOG 0236 — 54 Gy/3 fx peripheral; RTOG 0813 5 fx for central), unresectable stage III NSCLC PACIFIC (CRT + durvalumab 12 mo consolidation), limited-stage SCLC INT 0096 Turrisi (45 Gy BID + cisplatin/etoposide; CONVERT 66 Gy/33 fx alternative), PCI 25 Gy/10 fx for LS-SCLC responders, oligometastatic SABR-COMET (Palma), mesothelioma IMRT, esophageal — see GI.

~8%

GI Cancers

Esophageal CROSS regimen (carbo/taxol weekly + 41.4 Gy/23 fx then surgery), rectal total neoadjuvant therapy (PRODIGE 23, RAPIDO short-course or long-course CRT), anal squamous cell carcinoma Nigro regimen (5-FU/MMC + 50.4-59.4 Gy), pancreatic locally advanced — induction FOLFIRINOX or gem/nab then CRT or SBRT, hepatocellular SBRT 27.5-50 Gy/5 fx adapted to Child-Pugh, gastric adjuvant CRT (INT 0116 MacDonald), cholangiocarcinoma.

~8%

GU Cancers

Prostate hypofractionation CHHiP (60 Gy/20 fx) and PACE-B SBRT (36.25 Gy/5 fx), short-term ADT 4-6 months for unfavorable intermediate-risk, long-term ADT 18-36 months for high-risk (EORTC 22863 Bolla, RTOG 8531/9202), prostate LDR brachytherapy (I-125 145 Gy monotherapy, Pd-103 125 Gy), STAMPEDE arm H — prostate RT for low-volume metastatic, FLAME focal boost, Ra-223 (ALSYMPCA) and Lu-177 PSMA (VISION) for mCRPC, bladder trimodality (BC2001), seminoma stage I surveillance.

~5%

Gynecologic Cancers

Locally advanced cervical cancer — definitive concurrent cisplatin (40 mg/m^2 weekly) + EBRT 45-50.4 Gy then HDR/LDR brachytherapy boost to HR-CTV D90 EQD2 ≥85-90 Gy (EMBRACE, RetroEMBRACE), endometrial adjuvant vaginal cuff brachytherapy 7 Gy x 3 at 0.5 cm (PORTEC-2), early-stage cervical surgery vs RT, vulvar concurrent CRT, ovarian (limited RT role), uterine sarcoma, gestational trophoblastic disease.

~5%

Pediatric Tumors

Medulloblastoma — average-risk 23.4 Gy CSI + 54 Gy boost, high-risk 36 Gy CSI; proton CSI to spare anterior structures, ependymoma focal 54-59.4 Gy with proton preference, Wilms tumor 10.8 Gy flank for stage III FH, Ewing sarcoma definitive ~55.8 Gy or postop, rhabdomyosarcoma per COG (36-50.4 Gy), neuroblastoma 21 Gy primary site for high-risk, Hodgkin per pediatric ISRT, late-effects mitigation.

~5%

Hematologic Malignancies

Hodgkin lymphoma involved-site RT (ISRT) replacing IFRT, HD10 — 20 Gy non-inferior to 30 Gy in favorable early-stage post-ABVD, DLBCL consolidation RT 30-36 Gy after R-CHOP, MALT lymphoma low-dose RT (4 Gy x 2 — FoRT trial), TBI 12 Gy in 6 BID + cyclophosphamide for ALL allogeneic HCT (FORUM), TSEBT for mycosis fungoides (Stanford 6-field, 30-36 Gy or low-dose 12 Gy), tumor lysis syndrome with bulky lymphoma RT.

~3%

Palliative Radiation

Uncomplicated bone metastases — single-fraction 8 Gy (Dutch BMS, RTOG 9714, ASTRO Choosing Wisely), spinal cord compression 8 Gy x 1 / 20 Gy/5 fx / 30 Gy/10 fx (SCORAD; Patchell — surgery + RT > RT alone in selected), SVC syndrome hypofractionated (often 30 Gy/10 fx), brain metastases palliative WBRT 20 Gy/5 fx or 30 Gy/10 fx with memantine, hemibody RT (largely supplanted), end-of-life pain management.

~5%

Normal Tissue Tolerance & Toxicity

QUANTEC constraints — spinal cord Dmax ~50 Gy (<1% myelopathy), parotid mean <26 Gy (xerostomia), heart V25 < 10% (long-term cardiac mortality), lung V20 < 35% conventional / V20 < 10% SBRT (pneumonitis), esophageal V60 (esophagitis with concurrent chemo), liver mean <30 Gy (RILD), kidney mean <15-18 Gy, bowel V45, skin reactions (~20-30 Gy onset), late effects in pediatric patients, second malignancy risk, re-irradiation BED accounting (Nieder).

~5%

Radiation Safety, QA & Regulation

10 CFR Part 20 dose limits (50 mSv whole-body occupational, 5 mSv pregnancy), 10 CFR Part 35 medical use of byproduct material and Authorized User status, 10 CFR 35.3045 medical event reporting (24-hour notification, 15-day report), ALARA principles (time/distance/shielding), AAPM TG-51 (photon/electron beam absolute dose calibration), TG-43 brachytherapy dosimetry, TG-100 risk-based QM with FMEA, TG-142 linac QA (daily/monthly/annual), Joint Commission Universal Protocol time-out, RO-ILS (ASTRO/AAPM PSO), acute radiation syndrome thresholds.

How to Pass the ABPS Radiation Oncology Exam

What You Need to Know

Passing score: Criterion-referenced scaled score set by BCRO (modified Angoff standard)
Exam length: 200 questions
Time limit: ~4 hours CBT
Exam fee: ~$2,500 examination fee (ABPS/BCRO 2026 — verify current schedule)

Keys to Passing

Complete 500+ practice questions
Score 80%+ consistently before scheduling
Focus on highest-weighted sections
Use our AI tutor for tough concepts

ABPS Radiation Oncology Study Tips from Top Performers

1Memorize the QUANTEC normal tissue dose constraints cold — they are heavily tested. Spinal cord Dmax ~50 Gy (<1% myelopathy), parotid mean <26 Gy at least one gland (xerostomia), heart V25 < 10% (<1% long-term cardiac mortality at 15 yr per Marks et al), lung V20 < 35% conventional with mean <20 Gy (and V20 < 10% for SBRT), liver mean <30 Gy (RILD), kidney mean <15-18 Gy. Pair these with disease-specific OARs (e.g., bowel V45 in pelvis).

2Know landmark fractionation trials by name and regimen: Stupp (60 Gy/30 fx + TMZ for GBM), Turrisi/INT 0096 (45 Gy BID for LS-SCLC), START B/Canadian (40-42.5 Gy/15-16 fx for breast), FAST-Forward (26 Gy/5 fx in 1 wk), CHHiP (60 Gy/20 fx prostate), PACE-B (36.25 Gy/5 fx prostate SBRT), CROSS (carbo/taxol + 41.4 Gy/23 fx for esophageal), PRODIGE 23/RAPIDO (TNT for rectal), Nigro (5-FU/MMC + 50.4-59.4 Gy for anal).

3For brain metastases, know RTOG 9005 SRS dose tiers (24 Gy ≤2 cm, 18 Gy 2.1-3 cm, 15 Gy 3.1-4 cm), RTOG 9508 (WBRT+SRS for solitary brain met), NRG CC001 (HA-WBRT + memantine reduces cognitive decline), and RTOG 0614 (memantine 20 mg/d during WBRT). Modern SRS-alone is preferred for limited brain mets (typically 1-10) per ASTRO/NCCN guidelines.

4Brachytherapy pearls: TG-43 dosimetry parameters (air kerma strength Sk, dose rate constant Lambda, geometry function, radial dose function, anisotropy function), HDR Ir-192 (avg E ~380 keV, t1/2 ~73.8 d), I-125 LDR prostate monotherapy 145 Gy / Pd-103 125 Gy, EMBRACE HR-CTV D90 EQD2 ≥85-90 Gy for cervical, PORTEC-2 vaginal cuff 7 Gy x 3 at 0.5 cm depth.

5Radiobiology essentials: 4 R's (Repair, Redistribution, Repopulation, Reoxygenation) + intrinsic Radiosensitivity. Linear-quadratic model alpha/beta ~10 Gy for early-responding tissues and most tumors, ~2-3 Gy for late-responding. OER ~2.5-3 for X-rays (drops to ~1 for high-LET). G2/M most radiosensitive, late S most resistant. Proton clinical RBE 1.1. Be able to compute BED and EQD2 fluently.

6Radiation safety and regulation: 10 CFR Part 20 dose limits (50 mSv occupational TEDE, 150 mSv lens, 500 mSv skin/extremity, 5 mSv declared pregnant worker over gestation), 10 CFR Part 35 Authorized User for unsealed (I-131, Lu-177, Y-90, Ra-223) and many sealed brachytherapy/SRS uses, 10 CFR 35.3045 medical event reporting (24-hour notification, 15-day written report). AAPM TG-51 (calibration), TG-43 (brachy), TG-100 (risk-based QM/FMEA), TG-142 (linac QA).

Frequently Asked Questions

What is the ABPS Radiation Oncology Certification Examination?

The ABPS Radiation Oncology Certification Examination is administered by the Board of Certification in Radiation Oncology (BCRO) under the American Board of Physician Specialties (ABPS). It validates the competencies required of practicing radiation oncologists across radiobiology and radiation physics, treatment planning (3DCRT, IMRT, VMAT, SBRT, brachytherapy, protons), site-specific disease management (CNS, head and neck, breast, thoracic, GI, GU, gynecologic, hematologic, pediatric), palliative radiation, normal tissue tolerance and toxicity, and radiation safety/QA. ABPS is a non-ABMS multispecialty board with credentialing pathways recognized in select hospital and managed-care settings.

Who is eligible to take the BCRO Radiation Oncology exam?

Candidates must hold an MD, DO, or equivalent doctoral medical degree with a valid unrestricted medical license and have completed an accredited radiation oncology residency (ACGME or equivalent) or a BCRO-recognized international training pathway. Candidates submit documentation of training, hospital privileges, and case logs as required, along with letters of reference attesting to clinical competence in radiation oncology practice. Candidates should always verify the most current eligibility criteria on the ABPS BCRO website.

What is the format of the exam?

The BCRO Radiation Oncology exam is a computer-based test of single-best-answer multiple-choice questions delivered at secure CBT testing centers. Items are blueprinted to the BCRO content outline covering radiobiology and radiation physics, treatment planning and delivery, site-specific clinical oncology (CNS, head and neck, breast, thoracic, GI, GU, gynecologic, hematologic, pediatric), palliative radiation, normal tissue tolerance, and radiation safety/QA. Verify the current item count, time limit, and testing logistics on the ABPS BCRO schedule.

How much does the 2026 exam cost?

The 2026 BCRO Radiation Oncology examination fee is approximately $2,500 — always verify the current schedule on the ABPS website. Candidates should also budget for travel to the testing center, study materials (textbooks such as Hall and Giaccia Radiobiology, Khan Physics of Radiation Therapy, Perez and Brady Principles and Practice of Radiation Oncology, Halperin Pediatric Radiation Oncology), high-volume practice question banks, and ongoing Continuous Certification fees after passing. Cancellation and refund policies follow the BCRO schedule with decreasing refunds as the exam date approaches.

When is the 2026 exam administered?

BCRO offers the Radiation Oncology certification examination at multiple test administrations each year per the published ABPS/BCRO schedule. Candidates schedule specific appointments after their application is approved. Exact 2026 administration windows and registration deadlines should be confirmed on the ABPS BCRO Radiation Oncology page.

How is the exam scored?

BCRO uses criterion-referenced scaled scoring with a passing standard set by subject-matter experts using the modified Angoff method. A candidate's pass/fail result depends on performance relative to the fixed cut-score, not on other candidates. Score reports typically include domain-level feedback so candidates know their strongest and weakest content areas to direct any retake preparation.

What are the highest-yield topics for the exam?

Highest-yield topics include the Stupp protocol for GBM, RTOG 1016/De-ESCALaTE in HPV+ oropharynx, START B and FAST-Forward breast hypofractionation, Darby cardiac dose-response, PACIFIC durvalumab consolidation in stage III NSCLC, CROSS for esophageal and PRODIGE 23/RAPIDO TNT for rectal, CHHiP/PACE-B prostate fractionation and EORTC 22863 long-term ADT, EMBRACE cervical brachytherapy targets, NRG CC001 hippocampal-avoidance WBRT + memantine, QUANTEC normal tissue constraints, AAPM TG-43/51/100/142 physics and QA, 10 CFR Part 20/35 regulations, and ALARA principles.

How should I study for this exam?

Use a structured 6-12 month plan layered on your clinical practice. Map preparation to the BCRO content outline: begin with radiobiology and radiation physics, move to treatment planning and brachytherapy, then drill site-specific disease (CNS, head and neck, breast, thoracic, GI, GU, gynecologic, hematologic, pediatric, palliative), and close with normal tissue tolerance and radiation safety/QA. Combine high-yield textbooks (Hall and Giaccia, Khan, Perez and Brady, Halperin, Gunderson and Tepper), landmark trial review (Stupp, START B, CROSS, PACIFIC, CHHiP, PACE-B, EMBRACE, NRG CC001), QUANTEC constraints, AAPM TG documents, and high-volume MCQ practice including 2-3 timed full-length mock exams.